Hims & Hers Health shares fell 12% in after-hours trading on Monday after the telehealth company missed second-quarter ...

Linda Yaccarino is taking the top job at eMed Population Health, a telehealth startup focused on GLP-1 weight loss drugs, ...

Investing.com -- Hims & Hers Health (NYSE: HIMS) stock edged lower on Tuesday, extending its 10% decline following disappointing earnings, as Novo Nordisk (NYSE: NVO) announced 14 new lawsuits ...

Just a month after her exit from Musk's X, the tech executive will lead the digital platform for GLP-1 health management ...

Weight loss and diabetes drugs on the market often do not achieve long-term weight loss for patients. GLP-1 drugs target brain neurons that control ...

For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with ...

Welcome to Contract Pharma’s annual ranking of the Top 20 Pharma and Biopharma Companies, based on fiscal year 2024 ...

Former X CEO Linda Yaccarino has been named CEO of eMed Population Health, a health company that says it provides a “digital health platform for GLP-1/GIP population health management.” This refers to ...

Investors must now underwrite opportunities with a “financing risk first” mindset, says Siddhi Capital cofounder Steven Finn.

Linda Yaccarino, the former CEO of the Elon Musk-owned social media platform X, has a new leadership gig in the weight loss ...

The post, at the company that focuses on care for GLP-1 users, comes after Yaccarino left Elon Musk's X in July.

Former X CEO Linda Yaccarino has taken the helm at eMed Population Health, marking a bold shift from social media to digital healthcare leadership amid rising demand for weight-loss drugs and ...